SCHEMBL25205366

SCHEMBL25205366

O=C1CN(C(=O)c2csc(-c3cnn(-c4ccccc4)c3)n2)CCN1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.44
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
NTRK1 P04629 5/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR2C P28335 2/20 0.37
CFTR P13569 1/20 0.37
GRM2 Q14416 1/20 0.37
PARP1 P09874 2/20 0.37
KDM5A P29375 1/20 0.36
SMO Q99835 1/20 0.36
CHEK1 O14757 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25230843 0.87 CHEK1 (0.45) PTGDR2HTR2CGRM2KDM5ACHEK1
SCHEMBL25551048 0.84 HTR2C (0.50) PTGDR2MEN1RAB9AKMT2AL3MBTL1
SCHEMBL25217041 0.83 CHEK1 (0.43) PTGDR2HTR2CPARP1KDM5ACHEK1
SCHEMBL25552703 0.83 HTR2C (0.52) PTGDR2MEN1RAB9AKMT2AL3MBTL1
SCHEMBL25222071 0.82 KDM5A (0.44) PTGDR2HTR2CGRM2KDM5ACHEK1
SCHEMBL25207419 0.82 KDM5A (0.44) PTGDR2HTR2CGRM2KDM5ACHEK1
SCHEMBL31370726 0.81 PTGDR2 (0.41) PTGDR2RAB9AHTR2CCFTRGRM2
SCHEMBL25203568 0.81 PTGDR2 (0.42) PTGDR2HTR2CGRM2KDM5A
SCHEMBL25419155 0.81 REN (0.41) PTGDR2HTR2CGRM2KDM5ACHEK1
Hydrochloric Acid SCHEMBL25268211 0.81 KDM5A (0.44) PTGDR2HTR2CGRM2KDM5ACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US claimed
EP-4433162-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS Samsara Therapeutics Inc. (US) 2024-09-25 EP claimed
CN-118647613-A Autophagy inducing compounds and uses thereof, in particular for central nervous system diseases 轮回治疗公司 2024-09-13 CN claimed
WO-2023089052-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS Samsara Therapeutics Inc. (US) 2023-05-25 WO claimed
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US disclosed
EP-4183449-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF Samsara Therapeutics Inc. (US) 2023-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS SQSTM1, TFEB, BECN1 PTGDR2 4500/4885MEN1 2940/4885RAB9A 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.